Regulations continue to evolve globally within the distribution arena of the life sciences industry.
Good distribution practice (GDP) of medicinal products for human use (2013/C 343/01) and GDP of supply chain integrity has made a significant impact. There is an increased focus on companies being able to prove the quality and integrity of their drug product throughout the entire supply chain.
The industry is facing stricter compliance demands from regulations and regulatory agencies are not always given clear guidance.
Download this free whitepaper to find out more.